دورية أكاديمية
أعرض في EDS

Evaluation of Peripheral Blood Smear for Myelodysplasia in Breast Cancer Patients who Received Adjuvant Antracycline.

التفاصيل البيبلوغرافية
العنوان: Evaluation of Peripheral Blood Smear for Myelodysplasia in Breast Cancer Patients who Received Adjuvant Antracycline.
المؤلفون: Mutlu H; Department of Medical Oncology, Kayseri Education and Research Hospital, Kayseri, Turkey., Akca Z; Department of Radiation Oncology, Mersin Govermant Hospital, Mersin, Turkey., Teke HU; Department of Hematology, Kayseri Education and Research Hospital, Kayseri, Turkey., Ugur H; Department of Internal Medicine, Kayseri Education and Research Hospital, Kayseri, Turkey.
المصدر: The Eurasian journal of medicine [Eurasian J Med] 2011 Dec; Vol. 43 (3), pp. 173-6.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: AVES Country of Publication: Turkey NLM ID: 101557701 Publication Model: Print Cited Medium: Print ISSN: 1308-8734 (Print) Linking ISSN: 13088734 NLM ISO Abbreviation: Eurasian J Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Istanbul, Turkey : AVES
مستخلص: Objective: Therapy-related myeloid neoplasms (t-MN) account for approximately 10% to 20% of all cases of AML (acute myeloid leukemia), MDS (myelodysplastic syndrome) and MDS/MPN (myelodysplastic syndrome/myeloproliferative neoplasms), MDS, and MDS/MPN. In our study, we evaluated peripheral blood smear samples and hemogram values in breast cancer patients who were receiving adjuvant anthracycline regimens and were in remission.
Materials and Methods: A total of 78 patients receiving anthracycline-based adjuvant chemotherapy treatment from Kayseri Research and Training Hospital and Mersin State Hospital were enrolled in the study. Their adjuvant treatments had been completed at least 18 months prior to the study.
Results: Two patients complained of anemia (2.2%) (Hb<11 mg/dl), leukopenia was observed in seven patients (7.7%) (leukocytes<4000/ mm(3)), and thrombocytopenia was observed in four patients (4.4%) (PLT<150.000/mm(3)). In the blood smear samples, the following were observed: ovalomacrocytes (14%), macrocytes (37%), acanthocytes (1%), stomatocytes (12%), teardrops (12%), nucleated erythrocytes (1%), basophilic stippling (14%), and Howell-Jolly bodies (1%). Additionally, hypo-granulation (38%), Pelger-Huet abnormalities (26%), hypersegmentation (20%), immature granulocytes (8%), and blasts (6%) were observed. We also confirmed the presence of giant platelets (50%) and platelet hypogranulation (19%).
Conclusion: According to the peripheral blood smear assessments in our study, we suggest that breast cancer patients should be evaluated for MDS in the early stages, starting from month 18, even if the automated blood counts are normal.
References: Ann Oncol. 1992 Feb;3(2):107-11. (PMID: 1318741)
Br J Haematol. 1992 Oct;82(2):358-67. (PMID: 1419819)
J Clin Oncol. 2003 Apr 1;21(7):1195-204. (PMID: 12663705)
Presse Med. 2000 Jan 29;29(3):135-8. (PMID: 10686962)
Ann Oncol. 2003 May;14(5):693-8. (PMID: 12702521)
Int J Cancer. 2001 Oct 15;94(2):153-6. (PMID: 11668491)
N Engl J Med. 2005 Apr 14;352(15):1591-4. (PMID: 15829541)
Int J Hematol. 2000 Feb;71(2):144-52. (PMID: 10745624)
Scand J Haematol. 1985 Aug;35(2):197-200. (PMID: 2996123)
Blood. 1989 Jul;74(1):395-408. (PMID: 2752119)
Lancet. 1998 Sep 19;352(9132):930-42. (PMID: 9752815)
J Clin Oncol. 1989 Oct;7(10):1569-72. (PMID: 2778485)
J Clin Oncol. 2000 Aug;18(15):2836-42. (PMID: 10920131)
Blood. 1981 Oct;58(4):759-67. (PMID: 7272506)
Br J Haematol. 2000 Apr;109(1):13-23. (PMID: 10848777)
J Natl Cancer Inst. 1998 Nov 4;90(21):1587-9. (PMID: 9811303)
J Natl Cancer Inst. 1998 Nov 4;90(21):1601-8. (PMID: 9811309)
Ann Oncol. 2000 Oct;11(10):1289-94. (PMID: 11106118)
Semin Hematol. 1996 Jul;33(3):177-85. (PMID: 8819228)
Br J Haematol. 1994 Aug;87(4):743-5. (PMID: 7986716)
J Clin Oncol. 1986 Dec;4(12):1748-57. (PMID: 3783201)
J Natl Cancer Inst. 2008 Nov 5;100(21):1542-51. (PMID: 18957672)
J Clin Oncol. 2007 Jan 20;25(3):292-300. (PMID: 17159192)
فهرسة مساهمة: Keywords: Anthracycline; Breast cancer; Chemotherapy side effect; Leukemia; Myelodysplasia
Local Abstract: [Publisher, Turkish] Tedaviye bağlı myeloid neoplazmlar, tüm AML,MDS ve MDS/MPN vakalrının yaklaşık %10–20’sini oluşturmaktadır. Çalışmamızda adjuvant antrasiklinli kemoterapi rejimi almış remisyonda meme kanserli hastaların periferik yayma ve hemogram değerlerini araştırılmıştır. [Publisher, Turkish] Antrasiklin bazlı kemoterapi rejimi almış ve remisyonda olan toplam 78 hasta Kayseri Eğitim ve Araştırma Hastanesi ile Mersin Devlet Hastanesi’nden çalışmaya alınmıştır. Hastaların remisyonda olması ve tedaviyi en az 18 ay once tamamlamış olmasına dikkat edildi. [Publisher, Turkish] İki hastada anemi (%2.2) (Hb<11 mg/dl), 7 hastada lökopeni (%7.7) (Lökosit<4000/mm 3 ) ve 4 hastada trombositopeni (%4.4) (PLT<150.000/mm 3 ) saptandı. Ovalomakrositoz %14, makrositoz %37, akantositoz %1, stomatositoz %12, gözyaşı hücresi %12, çekirdekli eritrosit %1, bazofilik noktalanma %14 ve Howell-Jolly cisimciği %1 olarak tetkik edildi. %38 oranında hipogranülasyon, %26 Pelger-Huet anomalisi, %20 hipersegmentasyon, %8 immatür granülosit ve %6 blast vardı. Ayrıca %50 dev platelet ve %19 hipogranüle trombosit görüldü. [Publisher, Turkish] Çalışmamızın periferik yayma değerlendirme sonuçlarına gore meme kanserli hastaların myelodisplazik sendrom açısından, otomatik hemogram değerleri normal olsa da, erken dönemde, 18. aydan başlayarak rutin araştırılmasını önermekteyiz.
تواريخ الأحداث: Date Created: 20150123 Date Completed: 20150122 Latest Revision: 20201001
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4261399
DOI: 10.5152/eajm.2011.36
PMID: 25610187
قاعدة البيانات: MEDLINE
الوصف
تدمد:1308-8734
DOI:10.5152/eajm.2011.36